Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lorlatinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03107988
What this trial is testing

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Who this might be right for
Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium 65
Early research (Phase 1)Study completedNCT03961997
What this trial is testing

Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants

Who this might be right for
AdultDrug InteractionsHealthy Volunteers+1 more
Pfizer 16
Not applicableLooking for participantsNCT06487078
What this trial is testing

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Who this might be right for
ALK+ Non-Small-Cell Lung Carcinoma
Pfizer 90
Early research (Phase 1)Study completedNCT03184168
What this trial is testing

Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers

Who this might be right for
Healthy Volunteers
Pfizer 6
Testing effectiveness (Phase 2)UnknownNCT02927340
What this trial is testing

Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06378892
What this trial is testing

Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Who this might be right for
Non Small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano 45
Early research (Phase 1)Study completedNCT05224609
What this trial is testing

Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Who this might be right for
Moderate Hepatic ImpairmentSevere Hepatic ImpairmentHealthy Volunteers
Pfizer 21
Testing effectiveness (Phase 2)WithdrawnNCT05948462
What this trial is testing

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Who this might be right for
Lung CancerNon-small Cell Lung Cancer
SCRI Development Innovations, LLC
Early research (Phase 1)Study completedNCT02838264
What this trial is testing

Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

Who this might be right for
Healthy
Pfizer 16
Not applicableNo Longer AvailableNCT03178071
What this trial is testing

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Who this might be right for
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT07415005
What this trial is testing

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT01970865
What this trial is testing

PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Who this might be right for
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Pfizer 364
Post-approval studies (Phase 4)Not Yet RecruitingNCT07674368
What this trial is testing

Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed

Who this might be right for
ALK Fusion-positive Non-small Cell Lung Cancer
Hunan Cancer Hospital 29
Testing effectiveness (Phase 2)UnknownNCT03612154
What this trial is testing

Study of Lorlatinib in ROS1 Rearranged NSCLC

Who this might be right for
Nonsmall Cell Lung Cancer
National Cancer Center, Korea 35
Not applicableActive Not RecruitingNCT07567352
What this trial is testing

Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Who this might be right for
Non-Small-Cell LungALK-positive Advanced NSCLCALK-positive Non-small-cell Lung Cancer+1 more
Pfizer 200
Not applicableActive Not RecruitingNCT07556549
What this trial is testing

Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Who this might be right for
Non-Small Cell Lung Cancer ALK-positive
Pfizer 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT04127110
What this trial is testing

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 68
Testing effectiveness (Phase 2)UnknownNCT04292119
What this trial is testing

Lorlatinib Combinations in Lung Cancer

Who this might be right for
Lung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more
Massachusetts General Hospital 96
Early research (Phase 1)Not Yet RecruitingNCT07782359
What this trial is testing

Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

Who this might be right for
Lung Cancer
University of Chicago 30
Post-approval studies (Phase 4)Active Not RecruitingNCT06282874
What this trial is testing

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Who this might be right for
Carcinoma, Non-Small-Cell LungBrain MetastasesLeptomeningeal Metastasis
Guangdong Association of Clinical Trials 41
Next Page